NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2016

Primary Completion Date

May 4, 2017

Study Completion Date

June 2, 2017

Conditions

Chronic Heart Failure

Interventions

DRUG

elamipretide

Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days

DRUG

Placebo

Subcutaneous injection of placebo administered once daily for 28 consecutive days

Trial Locations (9)

Clinical Centre of Serbia, Clinic for Cardiology, Belgrade

"Clinical Hospital Center Dr Dragiša Mišović-Dedinje, Department of Cardiology", Belgrade

"Clinical Hospital Center Zvezdara, Department of Cardiology", Belgrade

"Clinical Hospital Center Bežanijska Kosa, Department of Cardiology", Belgrade

"Clinical Hospital Center Zemun, Department of Cardiology", Belgrade

Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin

German Heart Center, Berlin

Clinical Center Niš, Clinic for Cardiology, Niš

Institute for Cardiovascular Diseases Vojvodina, Clinic for Cardiology, Kamenitz

All Listed Sponsors

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

SCIRENT Clinical Research and Science d.o.o.

UNKNOWN

lead

Stealth BioTherapeutics Inc.

INDUSTRY